Currently, ABBV-8E12, an antibody against aggregated, extracellular tau, is in two Phase II trials targeting PSP patients and MCI subjects with positive amyloid scan (NCT03391765; NCT02880956). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.